StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) stock

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$6.38−0.61 (-8.73%)

Close on Nov 20, 2026Market cap $24.43MP/E –Yield –

Pelthos Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was -$22.69M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.69M–
FY2024Dec 31, 2024-$5.79M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.67M–
Q1 FY2026Mar 31, 2026-$13.32M–
Q2 FY2025Jun 30, 2025-$447.00K–
Q1 FY2025Mar 31, 2025-$632.00K–

More Pelthos Therapeutics figures

See a number that looks wrong?